These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32318637)

  • 41. Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment.
    Skrede S; Fernø J; Bjørndal B; Brede WR; Bohov P; Berge RK; Steen VM
    PLoS One; 2012; 7(11):e50853. PubMed ID: 23226405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls.
    Stogios N; Hamel L; Smith E; Sanches M; Remington G; Voineskos A; Dash S; Graff-Guerrero A; Hahn M; Agarwal SM
    PLoS One; 2022; 17(11):e0277211. PubMed ID: 36441736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.
    Albaugh VL; Judson JG; She P; Lang CH; Maresca KP; Joyal JL; Lynch CJ
    Mol Psychiatry; 2011 May; 16(5):569-81. PubMed ID: 20308992
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.
    Kalinichev M; Rourke C; Daniels AJ; Grizzle MK; Britt CS; Ignar DM; Jones DN
    Psychopharmacology (Berl); 2005 Oct; 182(2):220-31. PubMed ID: 16001110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
    Citrome L; Holt RI; Walker DJ; Hoffmann VP
    Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic Response to Olanzapine in Healthy Chinese Subjects with rs7093146 Polymorphism in Transcription Factor 7-like 2 Gene (TCF7L2): A Prospective Study.
    Li Q; Guo D; Yang H; Ye Z; Huang J; Shu Y
    Basic Clin Pharmacol Toxicol; 2017 Jun; 120(6):601-609. PubMed ID: 27983772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment.
    Minet-Ringuet J; Even PC; Valet P; Carpéné C; Visentin V; Prévot D; Daviaud D; Quignard-Boulange A; Tomé D; de Beaurepaire R
    Mol Psychiatry; 2007 Jun; 12(6):562-71. PubMed ID: 17211438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
    Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
    Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
    Bret P; Bonnet F; Bret MC; Jaffré A
    Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels.
    Roerig JL; Steffen KJ; Mitchell JE; Crosby RD; Gosnell BA
    J Clin Psychopharmacol; 2008 Feb; 28(1):21-6. PubMed ID: 18204336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
    Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
    Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.
    Lauriello J; Lambert T; Andersen S; Lin D; Taylor CC; McDonnell D
    J Clin Psychiatry; 2008 May; 69(5):790-9. PubMed ID: 18452346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
    Schmidt-Kraepelin C; Feyerabend S; Engelke C; Riesbeck M; Meisenzahl-Lechner E; Verde PE; Correll CU; Kluge M; Makiol C; Neff A; Lange C; Englisch S; Zink M; Langguth B; Poeppl TB; Reske D; Gouzoulis-Mayfrank E; Gründer G; Hasan A; Brockhaus-Dumke A; Jäger M; Baumgärtner J; Leucht S; Cordes J;
    Lancet Psychiatry; 2022 Apr; 9(4):291-306. PubMed ID: 35276079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.
    Kamath V; Jones CN; Yip JC; Varasteh BB; Cincotta AH; Reaven GM; Chen YD
    Diabetes Care; 1997 Nov; 20(11):1697-701. PubMed ID: 9353611
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice.
    Oxenkrug G; Summergrad P
    Mol Neurobiol; 2020 Jan; 57(1):135-138. PubMed ID: 31515691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
    Crawford AM; Beasley CM; Tollefson GD
    Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.